Last reviewed: June 15, 2026
Last updated: June 15, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
GLP-1 medications like semaglutide have demonstrated significant metabolic benefits for weight loss and diabetes management, with clinical trials showing sustained weight reductions of 15–22% in some populations. However, pregnancy introduces a different clinical scenario, and patients and providers must carefully weigh the evidence before continuing or initiating these therapies during conception and gestation.
What Do Animal Studies Tell Us About GLP-1 in Pregnancy?
Animal reproduction studies conducted on semaglutide and tirzepatide revealed dose-related effects on fetal development in rodent and rabbit models. At doses many times higher than typical human therapeutic doses, these compounds showed increased embryonic loss and structural abnormalities. However, animal model findings do not always translate directly to human pregnancy outcomes, and the relevance of supraphysiologic doses to real-world clinical practice remains unclear.
Tirzepatide, a dual GLP-1/GIP receptor agonist, demonstrated similar patterns in preclinical testing: effects appeared primarily at exposure levels substantially exceeding human therapeutic doses. Neither semaglutide nor tirzepatide has been formally studied in pregnant humans through randomized controlled trials, which means clinical decisions must rely on animal data, case reports, and physiologic reasoning rather than robust human evidence.
Current Clinical Guidance on GLP-1 Use During Pregnancy
Most major medical organizations, including the American College of Obstetricians and Gynecologists (ACOG) and the American Diabetes Association (ADA), recommend discontinuing GLP-1 medications upon pregnancy confirmation. This cautious approach reflects the absence of human safety data rather than proven harm at clinical doses. The reasoning centers on the principle that established, well-studied alternatives for weight and glucose management exist and carry better-documented safety profiles in pregnant populations.
PlexusDx advises patients of childbearing age who are considering pregnancy to discuss their medication plan with their prescribing provider and obstetrician. Treatment discontinuation timelines, transition strategies to other therapies, and individualized risk–benefit discussions should occur before conception or as soon as pregnancy is suspected. Abrupt discontinuation may affect metabolic control, so a thoughtful transition plan is essential.
Why Human Pregnancy Data for GLP-1 Medications Remains Limited
GLP-1 receptor agonists were not approved for weight loss until 2021 (semaglutide) and later (tirzepatide), making the pool of pregnant exposures relatively small. Additionally, many patients using these medications actively avoid pregnancy, and ethical constraints prevent deliberate randomized trials in pregnant populations. As a result, safety knowledge depends largely on spontaneous case reports, registry data, and animal studies—none of which provide the evidence density clinicians prefer when making recommendations.
Over time, observational registries and postmarketing surveillance may accumulate more human pregnancy outcomes, potentially refining current guidance. For now, the conservative approach reflects appropriate caution in the absence of reassuring human data, not proof of danger at therapeutic doses. Patients who became pregnant while using GLP-1 medications should contact their provider immediately to discuss their individual situation.
Personalized Health Planning: GLP-1, Genetic Factors, and Pregnancy Intent
Individual responses to GLP-1 medications depend partly on genetic variation in the GLP1R gene, GIPR signaling, and related metabolic pathways. PlexusDx Precision Peptide Genetic Test maps 14 distinct pathways and examines key variants such as GLP1R rs6923761 and GIPR rs1800437, which influence how your body processes these peptides. Understanding your peptide-pathway genetics allows for more informed discussions about long-term weight management strategies, especially if pregnancy is planned.
Patients planning pregnancy may benefit from a comprehensive consultation that integrates genetic insights with lifestyle optimization, alternative medication options (such as metformin for diabetes, or behavioral interventions for weight), and a timeline for medication transition. PlexusDx Semaglutide Injection (starting at $149/mo) and other therapies are effective tools for many patients, but pregnancy intent should shape the overall treatment roadmap. Genetic testing adds clarity to which metabolic pathways you're most responsive to, helping providers design a plan that works before, during, and after pregnancy.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Should I stop my GLP-1 medication if I'm planning to get pregnant?
Yes, current medical guidelines recommend discontinuing GLP-1 medications like semaglutide and tirzepatide before conception. Contact your healthcare provider and obstetrician to plan a safe transition off the medication, typically several weeks before trying to conceive. They can discuss alternative weight management and metabolic strategies suited to pregnancy.
What does animal testing data actually show about GLP-1 and pregnancy?
Rodent and rabbit studies found increased fetal loss and structural abnormalities only at doses many times higher than human therapeutic doses. These preclinical findings do not prove that standard clinical doses harm human pregnancy, but they do support the cautious approach of avoiding GLP-1 use until human safety data accumulates.
If I became pregnant while taking semaglutide, what should I do?
Contact your prescribing provider and obstetrician immediately to discuss your individual situation. Most clinicians will recommend stopping the medication, but your personal medical history and pregnancy circumstances warrant a personalized conversation. Do not abruptly discontinue without guidance, as this may affect metabolic control.
Are there safer weight management options if I'm pregnant or planning pregnancy?
Established alternatives include structured lifestyle programs, behavioral counseling, and in some cases pregnancy-safe medications like metformin (if glucose control is the goal). Your obstetrician and primary care provider can recommend evidence-based approaches tailored to your specific needs during pregnancy planning and gestation.
How does PlexusDx Precision Peptide Genetic Test help with pregnancy planning?
PlexusDx maps your GLP1R, GIPR, FTO, and MC4R variants across 14 pathways to show how you respond to GLP-1 compounds. Understanding your genetic profile helps your provider design a comprehensive weight and metabolic management plan for before, during, and after pregnancy—without relying solely on GLP-1 medications. Testing costs $99 after your first month of treatment.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Often Do You Increase the Dose of Ozempic? Navigating Your Personalized Weight Loss Journey
Can You Administer Ozempic Shot to Yourself While Sitting?